
Free to the world, a new COVID vaccine could help immunize low-income countries
Global News
A COVID-19 vaccine called CORBEVAX can be manufactured cheaply in low-income countries, without the complications of licensing, patents, or limited supply.
In the rush to vaccinate the world against COVID-19, researchers in Texas have made a breakthrough.
They’ve developed a vaccine called CORBEVAX that can be manufactured cheaply and quickly in low-income countries, without the complications of licensing, patents, or limited supply.
“We want to help the world,” says Dr. Maria Elena Bottazzi, who worked to develop the vaccine. “We think it’s a gamechanger.”
Developing nations have struggled with vaccination, after limited doses of expensive vaccines were snapped up by wealthier countries.
The vaccination rate in Canada, nearing 80 per cent, is in stark contrast with a nation like Nigeria, where only 2.2 per cent of the population is fully vaccinated.
“It just is incredibly iniquitous that low-income countries cannot get access to vaccines that will enable them to save their own lives,” says Dr. Keith Martin, a former MP and now executive director of the Consortium of Universities for Global Health in Washington, D.C. Martin, represented Esquimalt—Juan de Fuca from 1993 to 2011.
CORBEVAX could help close the gap.
Unlike the mRNA vaccines used in high-income nations, CORBEVAX is produced the same way as more traditional immunizations. The shot uses synthetic virus proteins to induce an immune response, without causing disease — the same way the hepatitis B vaccine works.










